Comparison of Clinical Advantage between Topiroxostat and Febuxostat in Hemodialysis Patients
To determine the response of hemodialysis (HD) patients to topiroxostat after a switch from febuxostat, we evaluated the efficacy, tolerability, and serum concentration of topiroxostat in HD patients after the switch. In this 16-month prospective observational study, we assessed the serum uric acid...
Saved in:
| Published in | Biological & pharmaceutical bulletin Vol. 40; no. 9; pp. 1463 - 1467 |
|---|---|
| Main Authors | , , , |
| Format | Journal Article |
| Language | English Japanese |
| Published |
Japan
The Pharmaceutical Society of Japan
2017
Pharmaceutical Society of Japan Japan Science and Technology Agency |
| Subjects | |
| Online Access | Get full text |
Cover
Loading…
| Abstract | To determine the response of hemodialysis (HD) patients to topiroxostat after a switch from febuxostat, we evaluated the efficacy, tolerability, and serum concentration of topiroxostat in HD patients after the switch. In this 16-month prospective observational study, we assessed the serum uric acid (UA) levels, other laboratory data, and serum topiroxostat concentrations of 10 HD patients who had been receiving febuxostat at a dose of 10 mg/d for over 1 year. No statistical difference was observed between the tolerability index at baseline and 16 months after the switch to topiroxostat. Serum UA after the switch in all patients (attained serum UA levels of ≤6 mg/dL) was 5.6±1.7 mg/dL (60%) at baseline, 4.9±0.5 mg/dL (100%) at 6 months and 5.7±0.4 mg/dL (50%) at 16 months (p=0.25), respectively. In patients with baseline serum UA levels >6 mg/dL, serum UA was significantly reduced at 6 and 16 months compared with baseline. Minimum serum concentrations of serum topiroxostat were lower than the limit of quantification (<25 ng/mL). Our results indicate that a switch from febuxostat 10 mg/d to topiroxostat 40 mg/d might reduce serum UA levels, with no change in other clinical laboratory data over the long term. These effects were more frequent in patients with high serum UA levels. Furthermore, topiroxostat therapy was more cost effective than febuxostat therapy. Thus, topiroxostat therapy could be a better treatment option for HD patients who develop high serum UA levels after febuxostat 10 mg/d administration. |
|---|---|
| AbstractList | To determine the response of hemodialysis (HD) patients to topiroxostat after a switch from febuxostat, we evaluated the efficacy, tolerability, and serum concentration of topiroxostat in HD patients after the switch. In this 16-month prospective observational study, we assessed the serum uric acid (UA) levels, other laboratory data, and serum topiroxostat concentrations of 10 HD patients who had been receiving febuxostat at a dose of 10 mg/d for over 1 year. No statistical difference was observed between the tolerability index at baseline and 16 months after the switch to topiroxostat. Serum UA after the switch in all patients (attained serum UA levels of ≤6 mg/dL) was 5.6±1.7 mg/dL (60%) at baseline, 4.9±0.5 mg/dL (100%) at 6 months and 5.7±0.4 mg/dL (50%) at 16 months (p=0.25), respectively. In patients with baseline serum UA levels >6 mg/dL, serum UA was significantly reduced at 6 and 16 months compared with baseline. Minimum serum concentrations of serum topiroxostat were lower than the limit of quantification (<25 ng/mL). Our results indicate that a switch from febuxostat 10 mg/d to topiroxostat 40 mg/d might reduce serum UA levels, with no change in other clinical laboratory data over the long term. These effects were more frequent in patients with high serum UA levels. Furthermore, topiroxostat therapy was more cost effective than febuxostat therapy. Thus, topiroxostat therapy could be a better treatment option for HD patients who develop high serum UA levels after febuxostat 10 mg/d administration. To determine the response of hemodialysis (HD) patients to topiroxostat after a switch from febuxostat, we evaluated the efficacy, tolerability, and serum concentration of topiroxostat in HD patients after the switch. In this 16-month prospective observational study, we assessed the serum uric acid (UA) levels, other laboratory data, and serum topiroxostat concentrations of 10 HD patients who had been receiving febuxostat at a dose of 10 mg/d for over 1 year. No statistical difference was observed between the tolerability index at baseline and 16 months after the switch to topiroxostat. Serum UA after the switch in all patients (attained serum UA levels of ≤6 mg/dL) was 5.6±1.7 mg/dL (60%) at baseline, 4.9±0.5 mg/dL (100%) at 6 months and 5.7±0.4 mg/dL (50%) at 16 months (p=0.25), respectively. In patients with baseline serum UA levels >6 mg/dL, serum UA was significantly reduced at 6 and 16 months compared with baseline. Minimum serum concentrations of serum topiroxostat were lower than the limit of quantification (<25 ng/mL). Our results indicate that a switch from febuxostat 10 mg/d to topiroxostat 40 mg/d might reduce serum UA levels, with no change in other clinical laboratory data over the long term. These effects were more frequent in patients with high serum UA levels. Furthermore, topiroxostat therapy was more cost effective than febuxostat therapy. Thus, topiroxostat therapy could be a better treatment option for HD patients who develop high serum UA levels after febuxostat 10 mg/d administration. To determine the response of hemodialysis (HD) patients to topiroxostat after a switch from febuxostat, we evaluated the efficacy, tolerability, and serum concentration of topiroxostat in HD patients after the switch. In this 16-month prospective observational study, we assessed the serum uric acid (UA) levels, other laboratory data, and serum topiroxostat concentrations of 10 HD patients who had been receiving febuxostat at a dose of 10 mg/d for over 1 year. No statistical difference was observed between the tolerability index at baseline and 16 months after the switch to topiroxostat. Serum UA after the switch in all patients (attained serum UA levels of <=6 mg/dL) was 5.6+-1.7 mg/dL (60%) at baseline, 4.9+-0.5 mg/dL (100%) at 6 months and 5.7+-0.4mg/dL (50%) at 16 months (p=0.25), respectively. In patients with baseline serum UA levels >6 mg/dL, serum UA was significantly reduced at 6 and 16 months compared with baseline. Minimum serum concentrations of serum topiroxostat were lower than the limit of quantification (<25ng/mL). Our results indicate that a switch from febuxostat 10 mg/d to topiroxostat 40 mg/d might reduce serum UA levels, with no change in other clinical laboratory data over the long term. These effects were more frequent in patients with high serum UA levels. Furthermore, topiroxostat therapy was more cost effective than febuxostat therapy. Thus, topiroxostat therapy could be a better treatment option for HD patients who develop high serum UA levels after febuxostat 10 mg/d administration. |
| Author | Okajima, Hideo Yamada, Hitoshi Mitsuboshi, Satoru Nagai, Kazuhiko |
| Author_xml | – sequence: 1 fullname: Mitsuboshi, Satoru organization: Department of Pharmacy, Kaetsu Hospital – sequence: 2 fullname: Yamada, Hitoshi organization: Department of Pharmacy, Kaetsu Hospital – sequence: 3 fullname: Nagai, Kazuhiko organization: Department of Pharmacy, Kaetsu Hospital – sequence: 4 fullname: Okajima, Hideo organization: Department of Internal Medicine, Kaetsu Hospital |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/28867729$$D View this record in MEDLINE/PubMed |
| BookMark | eNpdkUFv1DAQRi1URLeFI1cUiQuXlLGd2PGxWtEWqVJ7KEdk2c4EvErsECdA_z3O7rJI-DC25advRs8X5CzEgIS8pXBFWdV8tKO9slSWAKypXpAN5ZUsa0brM7IBRZtS0Lo5Jxcp7QBAAuOvyDlrGiElUxvydRuH0Uw-xVDErtj2Pnhn-uK6_WnCbL5hYXH-hRiKpzj6Kf6OaTZzYUJb3KBdjlcfijscYutN_5x8Kh7N7DHM6TV52Zk-4Zvjfkm-3Hx62t6V9w-3n7fX96WTrJnLrpHWIXDmZM2QAdQtb7tWKssBHOWN7TorlGBOKI6NEw6ZEsIJSmsJaPgl-XDIHaf4Y8E068Enh31vAsYlaap4zRUDUWf0_X_oLi5TyNPtKSE5lypT5YFyU0xpwk6Pkx_M9Kwp6NW7zt519q733jP_7pi62AHbE_1XdAZuD0B-XQXHkE3jv94uSetjHzWDfWgFoPR6pJXga8khdV6Qk7aHpF1a_-fUykyzdz3uB6tAq7WcBjy9uu9m0hj4H5vPrpk |
| CitedBy_id | crossref_primary_10_1515_znc_2020_0074 crossref_primary_10_1002_ardp_202400137 crossref_primary_10_1016_j_ejmech_2021_114086 crossref_primary_10_14233_ajchem_2020_22390 crossref_primary_10_1016_j_ejmech_2021_113928 crossref_primary_10_1016_j_jorganchem_2018_01_018 crossref_primary_10_1080_14756366_2022_2163241 crossref_primary_10_1016_j_bmcl_2022_128907 crossref_primary_10_1016_j_jpba_2020_113470 |
| ContentType | Journal Article |
| Copyright | 2017 The Pharmaceutical Society of Japan Copyright Japan Science and Technology Agency 2017 |
| Copyright_xml | – notice: 2017 The Pharmaceutical Society of Japan – notice: Copyright Japan Science and Technology Agency 2017 |
| CorporateAuthor | aDepartment of Pharmacy Kaetsu Hospital bDepartment of Internal Medicine |
| CorporateAuthor_xml | – name: bDepartment of Internal Medicine – name: Kaetsu Hospital – name: aDepartment of Pharmacy |
| DBID | CGR CUY CVF ECM EIF NPM AAYXX CITATION 7QP 7QR 7TK 7U9 8FD FR3 H94 P64 7X8 |
| DOI | 10.1248/bpb.b17-00284 |
| DatabaseName | Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed CrossRef Calcium & Calcified Tissue Abstracts Chemoreception Abstracts Neurosciences Abstracts Virology and AIDS Abstracts Technology Research Database Engineering Research Database AIDS and Cancer Research Abstracts Biotechnology and BioEngineering Abstracts MEDLINE - Academic |
| DatabaseTitle | MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) CrossRef Virology and AIDS Abstracts Technology Research Database AIDS and Cancer Research Abstracts Chemoreception Abstracts Engineering Research Database Calcium & Calcified Tissue Abstracts Neurosciences Abstracts Biotechnology and BioEngineering Abstracts MEDLINE - Academic |
| DatabaseTitleList | MEDLINE MEDLINE - Academic Virology and AIDS Abstracts |
| Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Anatomy & Physiology Chemistry Pharmacy, Therapeutics, & Pharmacology |
| EISSN | 1347-5215 |
| EndPage | 1467 |
| ExternalDocumentID | 10_1248_bpb_b17_00284 28867729 cs7biolo_2017_004009_017_1463_14672955550 article_bpb_40_9_40_b17_00284_article_char_en |
| Genre | Journal Article Comparative Study Observational Study |
| GroupedDBID | --- 23N 2WC 5GY 6J9 ACGFO ACIWK ACPRK ADBBV AENEX AFFNX AFRAH ALMA_UNASSIGNED_HOLDINGS BAWUL BKOMP CS3 DIK DU5 E3Z EBS EJD F5P GX1 HH5 JMI JSF JSH KQ8 MOJWN OK1 P2P RJT RZJ TR2 XSB ABJNI .55 1CY 53G ABTAH AI. CGR CUY CVF ECM EIF NPM TKC VH1 X7M ZXP ZY4 AAYXX CITATION 7QP 7QR 7TK 7U9 8FD FR3 H94 P64 7X8 |
| ID | FETCH-LOGICAL-c728t-f87bce032c752e2005d3dfd79b300c138bffb6962c693e8c6ce2966c611570ea3 |
| ISSN | 0918-6158 |
| IngestDate | Thu Apr 11 16:46:48 EDT 2024 Fri Sep 13 03:27:53 EDT 2024 Fri Aug 23 01:03:12 EDT 2024 Fri May 24 00:04:18 EDT 2024 Fri May 31 15:04:05 EDT 2024 Thu Aug 17 20:25:26 EDT 2023 |
| IsDoiOpenAccess | true |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 9 |
| Keywords | topiroxostat hemodialysis serum concentration febuxostat serum uric acid level |
| Language | English Japanese |
| LinkModel | OpenURL |
| MergedId | FETCHMERGED-LOGICAL-c728t-f87bce032c752e2005d3dfd79b300c138bffb6962c693e8c6ce2966c611570ea3 |
| Notes | ObjectType-Article-2 SourceType-Scholarly Journals-1 ObjectType-Undefined-1 ObjectType-Feature-3 content type line 23 |
| OpenAccessLink | https://www.jstage.jst.go.jp/article/bpb/40/9/40_b17-00284/_article/-char/en |
| PMID | 28867729 |
| PQID | 1935673379 |
| PQPubID | 1966364 |
| PageCount | 5 |
| ParticipantIDs | proquest_miscellaneous_1935392065 proquest_journals_1935673379 crossref_primary_10_1248_bpb_b17_00284 pubmed_primary_28867729 medicalonline_journals_cs7biolo_2017_004009_017_1463_14672955550 jstage_primary_article_bpb_40_9_40_b17_00284_article_char_en |
| PublicationCentury | 2000 |
| PublicationDate | 2017-00-00 |
| PublicationDateYYYYMMDD | 2017-01-01 |
| PublicationDate_xml | – year: 2017 text: 2017-00-00 |
| PublicationDecade | 2010 |
| PublicationPlace | Japan |
| PublicationPlace_xml | – name: Japan – name: Tokyo |
| PublicationTitle | Biological & pharmaceutical bulletin |
| PublicationTitleAlternate | Biol Pharm Bull |
| PublicationYear | 2017 |
| Publisher | The Pharmaceutical Society of Japan Pharmaceutical Society of Japan Japan Science and Technology Agency |
| Publisher_xml | – name: The Pharmaceutical Society of Japan – name: Pharmaceutical Society of Japan – name: Japan Science and Technology Agency |
| References | 7) Oyama S, Hirose C, Hori K, Sugano K, Zhang J, Tamura M, Tomita K. Effects, safety, and plasma levels of topiroxostat and its metabolites in patients receiving hemodialysis. Renal Replacement Therapy, 2, 56 (2016). 11) Mayer MD, Khosravan R, Vernillet L, Wu JT, Joseph-Ridge N, Mulford DJ. Pharmacokinetics and pharmacodynamics of febuxostat, a new non-purine selective inhibitor of xanthine oxidase in subjects with renal impairment. Am. J. Ther., 12, 22–34 (2005). 1) Johnson RJ, Kang DH, Feig D, Kivlighn S, Kanellis J, Watanabe S, Tuttle KR, Rodriguez-Iturbe B, Herrera-Acosta J, Mazzali M. Is there a pathogenetic role for uric acid in hypertension and cardiovascular and renal disease? Hypertension, 41, 1183–1190 (2003). 12) Seki M, Yabuno K, Miyawaki K, Miwa Y, Tomono K. Loading regimen required to rapidly achieve therapeutic trough plasma concentration of teicoplanin and evaluation of clinical features. Clin Pharmacol, 4, 71–75 (2012). 4) Nakazawa T, Miyata K, Omura K, Iwanaga T, Nagata O. Metabolic profile of FYX-051 (4-(5-pyridin-4-yl-1H-[1,2,4]triazol-3-yl)pyridine-2-carbonitrile) in the rat, dog, monkey, and human: identification of N-glucuronides and N-glucosides. Drug Metab. Dispos., 34, 1880–1886 (2006). 14) Kobayashi S, Ogura M, Hosoya T. Acute neutropenia associated with initiation of febuxostat therapy for hyperuricaemia in patients with chronic kidney disease. J. Clin. Pharm. Ther., 38, 258–261 (2013). 8) Grabowski BA, Khosravan R, Vernillet L, Mulford DJ. Metabolism and excretion of [14C] febuxostat, a novel nonpurine selective inhibitor of xanthine oxidase, in healthy male subjects. J. Clin. Pharmacol., 51, 189–201 (2011). 2) Cheung AK, Sarnak MJ, Yan G, Berkoben M, Heyka R, Kaufman A, Lewis J, Rocco M, Toto R, Windus D, Ornt D, Levey AS, HEMO Study Group. Cardiac disease in maintenance hemodialysis patients: result of the HEMO study. Kidney Int., 65, 2380–2389 (2004). 13) Tsuruta Y, Mochizuki T, Moriyama T, Itabashi M, Takei T, Tsuchiya K, Nitta K. Switching from allopurinol to febuxostat for the treatment of hyperuricemia and renal function in patients with chronic kidney disease. Clin. Rheumatol., 33, 1643–1648 (2014). 10) Mitsuboshi S, Yamada H, Nagai K, Okajima H. Switching from allopurinol to febuxostat: efficacy and tolerability in hemodialysis patients. J Pharm Health Care Sci., 1, 28 (2015). 16) Garg JP, Chasan-Taber S, Blair A, Plone M, Bommer J, Raggi P, Chertow GM. Effects of sevelamer and calcium-based phosphate binders on uric acid concentrations in patients undergoing hemodialysis: a randomized clinical trial. Arthritis Rheum., 52, 290–295 (2005). 3) Thurston MM, Phillips BB, Bourg CA. Safety and efficacy of allopurinol in chronic kidney disease. Ann. Pharmacother., 47, 1507–1516 (2013). 5) Hosoya T, Ogawa Y, Hashimoto H, Ohashi T, Sakamoto R. Comparison of topiroxostat and allopurinol in Japanese hyperuricemic patients with or without gout: a phase 3, multicentre, randomized, double-blind, double-dummy, active-controlled, parallel-group study. J. Clin. Pharm. Ther., 41, 290–297 (2016). 9) Hira D, Chisaki Y, Noda S, Araki H, Uzu T, Maegawa H, Yano Y, Morita SY, Terada T. Population pharmacokinetics and therapeutic efficacy of febuxostat in patients with severe renal impairment. Pharmacology, 96, 90–98 (2015). 6) Hosoya T, Ohno I, Nomura S, Hisatome I, Uchida S, Fujimori S, Yamamoto T, Hara S. Effects of topiroxostat on the serum urate levels and urinary albumin excretion in hyperuricemic stage 3 chronic kidney disease patients with or without gout. Clin. Exp. Nephrol., 18, 876–884 (2014). 15) Würzner G, Gerster JC, Chiolero A, Maillard M, Fallab-Stubi CL, Brunner HR, Burnier M. Comparative effects of losartan and irbesartan on serum uric acid in hypertensive patients with hyperuricaemia and gout. J. Hypertens., 19, 1855–1860 (2001). 11 12 13 14 15 16 1 2 3 4 5 6 7 8 9 10 |
| References_xml | – ident: 2 – ident: 3 – ident: 5 – ident: 4 – ident: 1 – ident: 12 – ident: 11 – ident: 10 – ident: 13 – ident: 16 – ident: 14 – ident: 15 – ident: 6 – ident: 9 – ident: 7 – ident: 8 |
| SSID | ssj0007023 ssib023156946 ssib002483627 ssib002822050 ssib017383521 |
| Score | 2.274224 |
| Snippet | To determine the response of hemodialysis (HD) patients to topiroxostat after a switch from febuxostat, we evaluated the efficacy, tolerability, and serum... |
| SourceID | proquest crossref pubmed medicalonline jstage |
| SourceType | Aggregation Database Index Database Publisher |
| StartPage | 1463 |
| SubjectTerms | Adult Aged febuxostat Febuxostat - adverse effects Febuxostat - pharmacokinetics Febuxostat - therapeutic use Female Follow-Up Studies Hemodialysis Humans Hyperuricemia - drug therapy Laboratories Male Middle Aged Nitriles - adverse effects Nitriles - pharmacokinetics Nitriles - therapeutic use Prospective Studies Pyridines - adverse effects Pyridines - pharmacokinetics Pyridines - therapeutic use Renal Dialysis serum concentration serum uric acid level topiroxostat Uric acid Uric Acid - blood Uricosuric Agents - adverse effects Uricosuric Agents - pharmacokinetics Uricosuric Agents - therapeutic use |
| Title | Comparison of Clinical Advantage between Topiroxostat and Febuxostat in Hemodialysis Patients |
| URI | https://www.jstage.jst.go.jp/article/bpb/40/9/40_b17-00284/_article/-char/en http://mol.medicalonline.jp/library/journal/download?GoodsID=cs7biolo/2017/004009/017&name=1463-1467e https://www.ncbi.nlm.nih.gov/pubmed/28867729 https://www.proquest.com/docview/1935673379/abstract/ https://search.proquest.com/docview/1935392065 |
| Volume | 40 |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| ispartofPNX | Biological and Pharmaceutical Bulletin, 2017/09/01, Vol.40(9), pp.1463-1467 |
| link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1da9swFBVZN9hgjC3dR7ZuaDDykiZ15G_Yw0JoCKN0hSWQlyEsW1rTEjvUNiz9HfvBu5Js2YFubMuDSGxZ2DnHV7qS7rkIfbCJ5XARiCEnzBk6YSSGUQCvu5uIcRQxEjpa7fPcmy-dzyt31en8bO1aKgs2im_vjCv5H1ThGOAqo2T_AVnTKByA74AvlIAwlH-F8bSdRHAwrYMcVabkQm7GqXdhLbLt-ib7kcnwIbVcMOOsrH4qsatNJgNIlDrJhVZazfeWe9fGRkqqbC_3JsJZW8JbxRcWecmyXOULHnyVbn1prEu0iRI1YJ2DLYEqZjY6-l5lxo5uy8v1dWamf6-jq_WmuiThWXueQgdk6t4Dev3GVMlnbFYNBhMVYdqelhwH4M5qOfcR10bZdnxwmHXYZ221tchTxc6wZYLB9Nt39g3EkfEObMtGDHpm6Ww6TSdYL_yff6Gz5dkZXZyuFvfQfeKD_6jMfeNU-ZZKGmjutFJuheZP9hrfG-k8uMoLpeLweKMX4LQQyu_9GjW-WTxFTyrHBE80y56hDk-76HCSAnqbHe5jtVVY_Ztd9HBapwnsov6FJsPuGC-aWL78WF1iZNF3h-hbw1acCVyzFRu24oqtuM1WDEjihq14neI2W3HN1udoOTtdTOfDKrnHMPZJUAxF4DOZq47Evku4nNtM7EQkfshsy4rHdsCEYF7okdgLbR7EMnMduOaxJ9WhLB7ZL9BBmqX8FcKJx5klhIh5AoNVYjHfFTz2YeTvJo6bkB7q10DQrdZwodL3BcQoIEYBMaoQ66GPGiZTrXq1VTXHoqEsTHVzVgZIgj3qoU974NLKVOQ0zn2lqUbli0FVxxlS-VWSVRbg4rrwsXroqOZDczX4WK7n27Yf9tB7cxpglmt7UcqzUteBBwaHoodeah6ZhyCBFK0k4es_N_4GPZK3p-cXj9BBcVPytzDiLtg79QL8AghM3V4 |
| link.rule.ids | 315,786,790,4043,27956,27957,27958 |
| linkProvider | ABC ChemistRy |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Comparison+of+Clinical+Advantage+between+Topiroxostat+and+Febuxostat+in+Hemodialysis+Patients&rft.jtitle=Biological+%26+pharmaceutical+bulletin&rft.au=Mitsuboshi%2C+Satoru&rft.au=Yamada%2C+Hitoshi&rft.au=Nagai%2C+Kazuhiko&rft.au=Okajima%2C+Hideo&rft.date=2017&rft.pub=Japan+Science+and+Technology+Agency&rft.issn=0918-6158&rft.eissn=1347-5215&rft.volume=40&rft.issue=9&rft.spage=1463&rft_id=info:doi/10.1248%2Fbpb.b17-00284&rft.externalDBID=NO_FULL_TEXT |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0918-6158&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0918-6158&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0918-6158&client=summon |